The investigation by Miralli et al. is one of the smaller studies that addressed whether co-occurring mutations in KEAP1, STK11, PBRM1 (Polybromo 1), and SMARCA4 (Mitotic Growth And Transcription Activator) genes could facilitate the identification of adenocarcinoma patients unresponsive to ICIs. The gene discussed is PBRM1; the disease is adenocarcinoma.